Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Accured Expenses (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Change in Accured Expenses data on record, last reported at -$3.5 million in Q2 2025.

  • For Q2 2025, Change in Accured Expenses fell 159.96% year-over-year to -$3.5 million; the TTM value through May 2025 reached -$5.9 million, down 458.08%, while the annual FY2025 figure was -$5.9 million, 458.08% down from the prior year.
  • Change in Accured Expenses reached -$3.5 million in Q2 2025 per LFCR's latest filing, down from -$2.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.8 million in Q2 2024 and bottomed at -$8.6 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is -$448555.6, with a median of -$1.2 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: plummeted 1031.12% in 2021, then surged 281.6% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $4.3 million in 2021, then soared by 31.39% to $5.6 million in 2022, then tumbled by 155.78% to -$3.1 million in 2023, then skyrocketed by 110.71% to $337000.0 in 2024, then tumbled by 1138.28% to -$3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$3.5 million in Q2 2025, -$2.5 million in Q1 2025, and $337000.0 in Q4 2024.